Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Precision Medicine Today: Predicting Treatment Response in Patient Subgroups

Carina Stanton  |  Issue: May 2020  |  

Carina Stanton is a freelance science journalist based in Denver.

References

  1. Curtis JR, Yang S, Chen L, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012 Feb;71(2):206–212.
  2. Montgomery A, Chen S, Homan P, et al. Single cell RNA-sequencing reveals distinct macrophage subsets in the joint with differing ontogenies during steady-state and arthritis [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).
  3. Yun H, Chen L, Xie F, et al. Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat‐to‐target principles? Results from the Rheumatology Informatics System for Effectiveness registry of the American College of Rheumatology. Arthritis Care Res (Hoboken). 2020 Feb;72(2):166–175.
  4. Bingham C, Kafka S, Black S, et al. Construct validation of PROMIS short form and profile-29 T-Scores with SF-36 in rheumatoid arthritis patients treated for 1 year: Results from a real world evidence-based study in the United States [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).

Related Articles

    Patient-Centered Care Model for RA Flares Could Improve Self-Management of Symptoms

    A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…

    An Evidence-Based Drug Update & Guidance for Rheumatologists

    ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…